Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
TG Therapeutics, Inc.
TGTX · SEC Filings
website
399
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company...
Price
63.38
Market Cap
9.7 B
Float
135.24 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about TGTX
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
TG Therapeutics, Inc.
TGTX · SEC Filings
135.24 M
Float
63.38
Price
9.7 B
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
NEW
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 9, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 6, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 5, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 8, 2025
News
TYPE
HEADLINE
FILED AT
8-K
NEW
TG Therapeutics Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance
Nov 9, 2026
8-K
TG Therapeutics Reports Q2 2026 Financial Results and Raises Full-Year BRIUMVI Revenue Guidance
Aug 3, 2026
8-K
TG Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jun 12, 2026
8-K
TG Therapeutics Announces Positive Phase 1 Results for Subcutaneous BRIUMVI
Jun 3, 2026
8-K
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial for BRIUMVI
May 27, 2026
8-K
TG Therapeutics Reports Strong Q1 2026 Financial Results and Raises Full-Year BRIUMVI Revenue Guidance
May 6, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
6,320,000 Shares-
Dec 16, 2020
424B5
Common Stock-
Dec 14, 2020
424B5
Shares of our common stock having an aggregate offering price of up to $400,000,000.
Nov 9, 2020
424B5
8,500,000 Shares
May 18, 2020
424B5
6,000,000 Shares
May 14, 2020
424B5
Shares of our common stock having an aggregate offering price of up to $200,000,000.
Mar 20, 2020
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Aug 11, 2025
S-3ASR
Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Aug 8, 2025
S-3ASR
Shares of our common stock having an aggregate offering price of up to $400,000,000.
Sep 2, 2022
S-8
Registration
Jun 24, 2022
S-3ASR
Registration
Sep 5, 2019
RW
Registration
Sep 5, 2019
Proxies
TYPE
HEADLINE
FILED AT
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 30, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 30, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Apr 18, 2025
PX14A6G
Form PX14A6G - Notice of exempt solicitation submitted by non-management
Jun 12, 2024
PX14A6G
Form PX14A6G - Notice of exempt solicitation submitted by non-management
Jun 10, 2024
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
BlackRock, Inc. (Filed by)
Oct 27, 2026
4
Charney Laurence N (Reporting)
Sep 14, 2026
144
Form 144 - Report of proposed sale of securities
Sep 10, 2026
4
Charney Laurence N (Reporting)
Aug 7, 2026
4
Lonial Sagar (Reporting)
Jun 15, 2026
4
HUME DANIEL (Reporting)
Jun 15, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
CT ORDER
Form CT ORDER - Confidential treatment order
Sep 17, 2018
EFFECT
Form EFFECT - Notice of Effectiveness
Jul 24, 2018
CORRESP
Form CORRESP - Correspondence
Jul 18, 2018
LETTER
Form UPLOAD - SEC-generated letter
Jul 17, 2018
CT ORDER
Form CT ORDER - Confidential treatment order
Apr 30, 2018
EFFECT
Form EFFECT - Notice of Effectiveness
Jun 14, 2017
